Medtronic (MDT)
NYSE:MDT
Want to see MDT full AI Analyst Report?
MDT Stock Chart & Stats
$86.19
$2.56(3.21%)
At close: 4:00 PM EST
$86.19
$2.56(3.21%)
Day’s Range― - ―
52-Week Range$73.31 - $106.33
Previous CloseN/A
Volume4.67M
Average Volume (3M)10.39M
Market Cap
$94.69B
Enterprise Value$121.69B
Total Cash (Recent Filing)$8.38B
Total Debt (Recent Filing)$28.07B
Price to Earnings (P/E)20.8
Beta0.37
Next Earnings
Aug 25, 2026EPS Estimate
1.39Next Dividend Ex-DateN/A
Dividend Yield2.76%
Share Statistics
EPS (TTM)3.59
Shares Outstanding1,283,885,000
10 Day Avg. Volume11,556,796
30 Day Avg. Volume10,392,761
Financial Highlights & Ratios
PEG Ratio0.75
Price to Book (P/B)2.25
Price to Sales (P/S)3.23
P/FCF Ratio20.87
Enterprise Value/Market Cap1.29
Enterprise Value/Revenue3.43
Enterprise Value/Gross Profit5.54
Enterprise Value/Ebitda13.01
Forecast
1Y Price Target
$99.32Price Target Upside15.23% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering20
EPS Forecast (FY)6.05
Revenue Forecast (FY)$38.24B
Bulls Say, Bears Say
Bulls Say
Cash Generation StrengthMedtronic's strong TTM operating cash flow (~$7.3B) and free cash flow (~$5.4B) provide durable financial flexibility. Robust FCF (≈0.73 of net income) supports sustained R&D, targeted M&A, dividends and buybacks, cushioning the business versus elective procedure cyclicality.
High-growth Franchise MomentumRapid share gains in cardiac ablation (CAS annualizing ~$2B, +78% worldwide), strong PFA uptake, growing Symplicity and Hugo robotics traction create multi-year product-led growth. These franchises expand procedure volumes and installed bases, driving recurring consumables and upgrade cycles.
Diversified Installed-base BusinessA broad portfolio across cardiovascular, diabetes, surgical, neuroscience and spine with a large installed base produces recurring revenue from disposables, service and software. This diversification reduces reliance on any single therapy and supports steady follow-on revenue streams.
Bears Say
Tariff & Trade HeadwindsManagement models roughly $250M of tariff-related costs for FY‑27 (≈20bps gross margin impact) and noted prior-quarter effects. Persistent tariff and trade uncertainty can chronically compress margins, force higher prices or require costly supply-chain adjustments, reducing long-term operating leverage.
TTM Balance-sheet InconsistencyThe pack flags an incomplete/implausible TTM balance-sheet snapshot (debt and equity shown as zero), undermining confidence in recent leverage and liquidity metrics. That data gap complicates reliable assessment of covenant exposure, financing flexibility and near-term capital allocation decisions.
Diabetes/MiniMed Separation UncertaintyMiniMed-related charges, royalty obligations and the partial IPO introduce structural earnings volatility and mix dilution. Uncertainty over separation timing, ongoing royalty payments and integration economics can pressure margins and EPS predictability until the Diabetes business separation and long-term arrangements are finalized.
Medtronic News
MDT FAQ
What was Medtronic’s price range in the past 12 months?
Medtronic lowest stock price was $73.31 and its highest was $106.33 in the past 12 months.
What is Medtronic’s market cap?
Medtronic’s market cap is $94.69B.
When is Medtronic’s upcoming earnings report date?
Medtronic’s upcoming earnings report date is Aug 25, 2026 which is in 81 days.
How were Medtronic’s earnings last quarter?
Medtronic released its earnings results on Jun 03, 2026. The company reported $1.55 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.01.
Is Medtronic overvalued?
According to Wall Street analysts Medtronic’s price is currently Undervalued.
Does Medtronic pay dividends?
Medtronic pays a Quarterly dividend of $0.71 which represents an annual dividend yield of 2.76%. See more information on Medtronic dividends here
What is Medtronic’s EPS estimate?
Medtronic’s EPS estimate is 1.39.
How many shares outstanding does Medtronic have?
Medtronic has 1,283,885,000 shares outstanding.
What happened to Medtronic’s price movement after its last earnings report?
Medtronic reported an EPS of $1.55 in its last earnings report, beating expectations of $1.54. Following the earnings report the stock price went up 5.695%.
Which hedge fund is a major shareholder of Medtronic?
Currently, no hedge funds are holding shares in MDT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Medtronic Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Company Description
Medtronic
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.
MDT Company Deck
MDT Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a predominantly positive operational and financial picture: strong quarterly and annual revenue growth, EPS outperformance, robust free cash flow, multiple high-growth product area accelerations (CAS, Symplicity, Hugo, Altaviva), and deliberate M&A/venture activity to drive future growth. Notable headwinds include tariffs and trade uncertainty, some product‑mix and Diabetes-related margin pressure, pockets of weakness in Structural Heart (TAVR) and select therapy areas, and near-term investment-driven SG&A/R&D increases. Management provided confident FY '27 guidance while conservatively modeling separation and tariff risks.View all MDT earnings summariesMDT Net sales Breakdown
36.56% Cardiovascular
29.06% Neuroscience
26.01% Medical Surgical
7.69% Diabetes
0.68% Other operating segment
MDT Stock 12 Month Forecast
Average Price Target
$99.32
▲(15.23% Upside)
Technical Analysis
Ownership Overview
0.07% Insiders
25.81% Mutual Funds
19.92% Other Institutional Investors
30.52% Public Companies and Individual Investors